# 2026-00907: DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats

2026-00907, Definition of “Cannabimimetic Agents” and Assignment of an Administration Controlled Substances Code Number for All “Cannabimimetic Agents”, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-01-20, effective 2026-02-19 (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-00907
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-00907
- Title: Definition of “Cannabimimetic Agents” and Assignment of an Administration Controlled Substances Code Number for All “Cannabimimetic Agents”
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 2297
- Published: 2026-01-20
- Effective: 2026-02-19
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats

## Summary

Starting February 19, 2026, the DEA is officially defining “cannabimimetic agents” and adding 18 new substances to this group, all still Schedule I drugs. They’re also simplifying things by giving most of these substances one single drug code, making tracking easier. This update affects manufacturers, law enforcement, and anyone handling these substances, but it won’t change their legal status or cause new fees.

## Abstract

The Drug Enforcement Administration is publishing this final rule to amend its regulations related to "cannabimimetic agents" by including the term's definition, identifying 18 additional substances that meet the definition, and consolidating most existing administration controlled substances code numbers (drug codes) into a single drug code number for substances that meet this definition. The listing for two schedule I "cannabimimetic agents" that are under international control, JWH-018 and AM2201, are moved to the "hallucinogens" paragraph of schedule I but retain their existing drug codes to facilitate quota and international reporting requirements. While this final rule does not change the current and continuing schedule I status for the 18 additional substances meeting the definition of "cannabimimetic agents," these and other substances meeting this definition will be assigned a new administration controlled substances code number once this final rule becomes effective.

## Effects PRIA read

- Eighteen substances formally listed: mixed, low. Starting February 19, 2026, DEA adds 18 additional named substances to the definition of “cannabimimetic agents.” All 18 substances remain Schedule I controlled substances, so their legal schedule status does not change.
- Single DEA drug code for most agents: benefit, low. DEA consolidates most existing administration controlled substances codes for cannabimimetic agents into a single drug code number 7000 when the rule takes effect on February 19, 2026, to simplify tracking and reporting.
- Two substances moved but keep existing codes: cost, low. JWH-018 and AM2201 are moved to 21 CFR 1308.11(d) but retain their existing drug codes (7118 and 7201) to facilitate quota and international reporting; upon that move, positional isomers of these two substances will be defined as Schedule I controlled substances.
- No new fees or reporting obligations: benefit, low. DEA states this final rule does not change the Schedule I status of listed substances, does not impose new regulatory controls, recordkeeping, reporting requirements, or information-collection burdens, and will not create new fees for handlers.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09
- [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09

## Sources
- [2026-00907 on federalregister.gov](https://www.federalregister.gov/documents/2026/01/20/2026-00907/definition-of-cannabimimetic-agents-and-assignment-of-an-administration-controlled-substances-code)
- [2026-00907 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-01-20/pdf/2026-00907.pdf)

## Related
- [Previous: 2026-00904, Commercial Non-Power Production or Utilization Facilities](https://policyrisk.com/federal-register/2026-00904)
- [Next: 2026-00909, Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing…](https://policyrisk.com/federal-register/2026-00909)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-00907 (as of 2026-06-11).